Buttery L D, Springall D R, Andrade S P, Riveros-Moreno V, Hart I, Piper P J, Polak J M
Department of Histochemistry, Royal Postgraduate Medical School, Hammersmith Hospital, London.
J Pathol. 1993 Dec;171(4):311-9. doi: 10.1002/path.1711710412.
Maintenance of blood flow is an important factor in sustaining tumour growth. Functional studies have previously demonstrated a reduction in tumour blood flow with selective inhibitors of nitric oxide (NO) synthesis, L-NAME (NG-nitro-L-arginine-methylester) and L-NMMA (NG-monomethyl-L-arginine), when administered locally to tumours derived from murine colon 26 adenocarcinoma and B16 melanoma cells. The type of NO synthase which might be responsible for this locally-derived NO and the site of synthesis was not described. Here we have investigated the distribution of immunoreactivity and the biochemical characteristics of the enzymes synthesizing NO in the same murine model. Adenocarcinoma (colon 26) or melanoma (B16) cells were introduced into a sponge matrix implanted subcutaneously in mice. After 7, 12, and 14 days, the implants were removed and frozen sections were immunostained with rabbit antisera to constitutive and inducible isoforms of NO synthase. Immunoreactivity with antisera to inducible NO synthase was detected in the vasculature of neoplastic implants, with and without the sponge, at 12 and 14 days. The enzyme was not evident in 7-day-old tumours, in non-neoplastic implants, in areas of tissue outside the tumour, or in adenocarcinoma or melanoma cells. Enzyme activity was measurable in homogenates of neoplastic implants removed at day 7 and was found to be Ca2+/calmodulin-independent. Immunoreactivity with antisera to inducible NO synthase was seen principally in the endothelium of newly-formed capillaries, identified by immunostaining for von Willebrand factor in serial sections. Immunoreactivity with antiserum to constitutive NO synthase was not evident in either neoplastic or non-neoplastic implants.(ABSTRACT TRUNCATED AT 250 WORDS)
维持血流是维持肿瘤生长的一个重要因素。功能研究先前已证明,当将一氧化氮(NO)合成的选择性抑制剂L-NAME(NG-硝基-L-精氨酸甲酯)和L-NMMA(NG-单甲基-L-精氨酸)局部应用于源自小鼠结肠26腺癌和B16黑色素瘤细胞的肿瘤时,肿瘤血流会减少。此前未描述可能负责这种局部产生的NO的NO合酶类型及其合成部位。在此,我们在同一小鼠模型中研究了免疫反应性的分布以及合成NO的酶的生化特性。将腺癌(结肠26)或黑色素瘤(B16)细胞植入皮下植入小鼠的海绵基质中。7、12和14天后,取出植入物,将冰冻切片用兔抗血清对NO合酶的组成型和诱导型同工型进行免疫染色。在12天和14天时,在有或没有海绵的肿瘤植入物的脉管系统中检测到对诱导型NO合酶抗血清的免疫反应性。在7天大的肿瘤、非肿瘤植入物、肿瘤外的组织区域或腺癌或黑色素瘤细胞中未发现该酶。在第7天取出的肿瘤植入物匀浆中可测量到酶活性,并且发现其不依赖于Ca2+/钙调蛋白。对诱导型NO合酶抗血清的免疫反应性主要见于新生毛细血管的内皮细胞,通过对连续切片中的血管性血友病因子进行免疫染色来鉴定。对组成型NO合酶抗血清的免疫反应性在肿瘤性或非肿瘤性植入物中均不明显。(摘要截短于250字)